Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.36 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369002 | 0.87 | LMNA (0.46) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL1222284 | 0.82 | LMNA (0.38) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL368773 | 0.81 | NAAA (0.38) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL368060 | 0.81 | POLB (0.33) | HPGDALDH1A1HSD17B10KDM4ERAB9A | |
| SCHEMBL15097362 | 0.81 | LMNA (0.37) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL368528 | 0.80 | LMNA (0.37) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL369105 | 0.78 | ALDH1A1 (0.36) | HPGDALDH1A1HSD17B10RNASEH1KDM4E | |
| SCHEMBL368710 | 0.77 | TLR9 (0.40) | HPGDLMNA | |
| SCHEMBL369106 | 0.76 | CYP19A1 (0.42) | HPGDLMNAALDH1A1USP2TSHR | |
| SCHEMBL823352 | 0.75 | KDM4E (0.54) | HPGDLMNAALDH1A1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| EP-2593460-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | Avexa Limited (AU) | 2013-05-22 | — | — | EP | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | HPGD 924/4885LMNA 3403/4885ALDH1A1 702/4885 |
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | HPGD 2087/4885LMNA 4293/4885ALDH1A1 1686/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | HPGD 924/4885LMNA 3403/4885ALDH1A1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.